Oral Presentations 6 TDM in Oncology

17:00 • 347 • Ruxolitinib pharmacokinetics and exposure–toxicity relationship in hematologic malignancies and immune-mediated diseases: a prospective observational study > F. François Girardin 17:13 • 26 • Population pharmacokinetics supports pembrolizumab de-escalation while meeting target exposure in advanced non-small cell lung cancer > A-K. Anna-Kristina Oma 17:26 • 667 • Evaluation of regorafenib treatment PERSOnalization based on therapeutic drug monitoring in patients with metastatic colorectal cancer (mCRC): RePERSO study. > C. Camille Tron 17:39 • 669 • Precision Phenotyping of UH2:U Using a Hierarchical Bayesian Flux Model > M. Marina Schlaepfer 17:52 • 719 • Phenotyping versus genotyping for the adaptation of 5-Fluorouracil therapy > B. Bénédicte Franck 18:05 • 84 • Higher ibrutinib exposure leads to higher risk of withdrawal due to toxicity > C. Cathrine Korsholm